EQS-News: Gerresheimer expands capacities for Medical Systems in the USA


Im Artikel erwähnte Wertpapiere: Gerresheimer I

EQS-News: Gerresheimer AG / Key word(s): Expansion
Gerresheimer expands capacities for Medical Systems in the USA

27.05.2024 / 13:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

Gerresheimer expands capacities for Medical Systems in the USA

  • Two-stage expansion of the Peachtree City, Georgia site
  • Total investment volume of around USD 180 million
  • More than 400 new jobs for skilled workers from the region
  • Ramp-up of production beginning end of 2024

Düsseldorf / Peachtree City, USA, May 27, 2024 – Gerresheimer, an innovative systems and solutions provider and global partner for the pharma, biotech and cosmetics industries, is significantly expanding its production capacities for medical systems such as inhalers and autoinjectors in the United States. In two expansion stages, Gerresheimer is expanding the production area at its Peachtree City site in the state of Georgia, USA, by around 18,000 m² (194,000 sqft). The company is investing a total of around 166 million euros (USD 180 million) in the construction and equipping of the two new buildings. Gerresheimer will create more than 400 new jobs in Peachtree City as part of the expansion. The company currently employs around 270 people at the site. With the expansion in Peachtree, Gerresheimer is also underscoring its leading market position as a system and solution provider for drug delivery systems in the North American market.

 "North America is an important growth market for us. The expansion of the site in Peachtree City is of great importance for our medical device business in the USA," says Dietmar Siemssen, CEO of Gerresheimer AG. "The expansion of this site is therefore currently one of the key projects in our global capacity expansions based on long-term customer contracts."

Construction work of the first expansion stage almost completed 

In the first stage of expansion, a new building section covering around 7,700 m² (83,000 sqft) was built directly next to the existing plant. Around 5,000 m² (53,800 sqft) are intended for ISO 14644-1 cleanroom class 9 production areas. After completion of the construction work, the installation of the specialized production technology will begin in the second half of 2024. At the end of 2024, ramp-up of production will start in the new section of the building. Also part of the new building is a new, automated high-bay warehouse. After completion of the first stage of expansion, the Peachtree City site will have a total of approximately 12,000 m² (130,000 sqft) of cleanroom class 8 and 9 production space.

Second expansion stage started – new factory hall with growth option

As part of the second stage of expansion of Gerresheimer's manufacturing capabilities in Peachtree City, a completely new 10,200 m² (110,000 sqft) plant is being built near Atlanta Regional Airport, approximately 2.6 km (1.6 mi) from the first production site, which will have an additional 7,200 m² (77,500 sqft) of cleanroom class 9 production space and also an automated high-bay warehouse. After the preparatory work for the access road and supply infrastructure, the construction of the new factory building will soon begin here. In the course of 2025, the installation of the production and assembly lines will follow, and production is also scheduled to start here towards the end of 2025. The factory site on which the new building is being built also offers enough space for future expansions.  

Becoming one of the largest employers in the region with over 400 new jobs

With the capacity expansions, Gerresheimer is creating more than 400 new jobs for skilled workers in Peachtree City. Once the expansion is complete, Gerresheimer will be one of the largest employers in the city, which is located about 40 km (25 miles) southwest of Atlanta, the capital of the state of Georgia, with around 700 employees.

At the Peachtree site, Gerresheimer produces medical devices such as inhalers, components for infusion sets, microinjectors, test cards for microbiological tests and autoinjectors, which can be used in diabetes and obesity therapy, among other things.


About Gerresheimer
As an innovative system and solution provider, Gerresheimer is the global partner for the pharmaceutical, biotech and cosmetics industries. The company offers a comprehensive portfolio of containment solutions for medicines, drug delivery systems and medical devices, as well as solutions for the healthcare industry. The range of services includes digital solutions for therapy support, drug pumps, syringes, pens, autoinjectors and inhalers as well as injection vials, ampoules, tablet containers, infusion, dropper and syrup bottles. Gerresheimer ensures that medications reach patients safely and can be administered reliably.
With 35 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for the regional markets. With around 12,000 employees, the company generated sales of around 2 billion euros in 2023. Gerresheimer AG is listed in the MDAX of the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6).

Contact Gerresheimer AG

Jutta Lorberg
Head of Corporate Communication
T +49 211 6181 264
Marion Stolzenwald
Senior Manager Corporate Communication
T +49 172 2424185

Investor Relations
Guido Pickert
Vice President Investor Relations
T +49 152 900 14145
Thomas Rosenke
Senior Manager Investor Relations
T: +49 211 6181-187

27.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

Language: English
Company: Gerresheimer AG
Klaus-Bungert-Str. 4
40468 Duesseldorf
Phone: +49-(0)211/61 81-00
Fax: +49-(0)211/61 81-121
E-mail: gerresheimer.ir@gerresheimer.com
Internet: http://www.gerresheimer.com
Indices: MDAX (Aktie)
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1911655

End of News EQS News Service

1911655  27.05.2024 CET/CEST

Im Artikel erwähnte Wertpapiere

Gerresheimer I 100,80 -0,59%

Populäre Aktien